Tài liệu Báo cáo khoa học: Neuronal growth-inhibitory factor (metallothionein-3): evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative brain pdf

MINIREVIEW Neuronal growth-inhibitory factor (metallothionein-3): evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative brain Claire Howells, Adrian K. West and Roger S. Chung Menzies Research Institute, University of Tasmania, Hobart, Australia Introduction Metallothioneins (MTs) are a family of unusual cyste- ine-rich (30%), 6–7 kDa proteins synthesized predomi- nantly by astrocytes within the brain. The MT3 isoform was first isolated and identified as a neuronal growth- inhibitory factor (GIF) in 1991, a brain-specific protein whose synthesis was notably deficient in the Alzheimer’s disease (AD) brain. It was found to possess a strong ability to impair neurite outgrowth and neuronal survival of cultured neurons, leading to its designation as GIF. It was later discovered that GIF shares approx- imately 70% amino-acid sequence similarity with the MT family of proteins, leading to its renaming as MT3. Most striking is the conservation within GIF of the unique cysteine motifs found in mammalian MTs. Given that GIF shares a biochemical structure similar to those of the other MT isoforms, it is not surprising that GIF has the characteristic metal-binding and reactive oxygen species (ROS) scavenging capabilities present in all MT isoforms. However, GIF has also been found to exhibit several unique biological proper- ties, suggesting that this MT isoform has different and distinct functions within the brain. Furthermore, the discovery and continued investigation of this brain-spe- cific MT isoform has led to intense interest in the roles of the entire MT family in the brain, with particular focus on the role of these proteins in the injured or neurodegenerative brain. Discovery of GIF AD is a neurodegenerative disease that leads to severe dementia and ultimately death. The pathological hallmarks of the disease are intracellular neurofibril- lary tangles, dystrophic neurites or curly fibres, and Keywords brain injury; metals; neuronal growth- inhibitory factor (GIF); neurodegenerative disease; oxidative stress Correspondence R. S. Chung, PhD, Private Bag 58, University of Tasmania, Hobart, Tasmania 7001, Australia Fax: +61 3 62262703 Tel: +61 3 62262657 E-mail: rschung@utas.edu.au (Received 27 November 2009, revised 13 March 2010, accepted 19 May 2010) doi:10.1111/j.1742-4658.2010.07718.x Neuronal growth-inhibitory factor, later renamed metallothionein-3, is one of four members of the mammalian metallothionein family. Metallothione- ins are a family of ubiquitous, low-molecular-weight, cysteine-rich proteins. Although neuronal growth-inhibitory factor shares metal-binding and reac- tive oxygen species scavenging properties with the other metallothioneins, it displays several distinct biological properties. In this review, we examine the recent developments regarding the function of neuronal growth-inhibi- tory factor within the brain, particularly in response to brain injury or during neurodegenerative disease progression. Abbreviations AD, Alzheimer’s disease; Ab, b-amyloid; CNS, central nervous system; GIF, neuronal growth-inhibitory factor; KO, knockout; MT, metallothionein; NO, nitric oxide; ROS, reactive oxygen species. FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS 2931 extracellular senile amyloid plaques. These physical alterations are often accompanied by aberrant neurite sprouting and significant neuronal loss, particularly within the cerebral cortex and hippocampus. One explanation for this impaired neuronal survival is that there may be decreased synthesis of a neurotrophic factor that promotes the survival and growth of neu- rons within the hippocampus and cerebral cortex in the AD brain. However, several studies observed that in fact the AD brain has elevated neurotrophic activity compared with the normal aged brain [1,2]. These studies suggested that a soluble extract from AD brain significantly enhanced neuronal survival and neurite outgrowth of cultured cortical neurons in comparison with aged brain extract. It was proposed that this increased neurotrophic activity could be a cause of the abnormal neurofibril- lary changes that occur within the AD brain. Accord- ingly, if neurite sprouting was left unchecked, then this process could lead to neuronal exhaustion and eventu- ally cell death, partly explaining the vast neuronal loss in the AD brain. Further investigation of the increased neurotrophic activity of the AD brain revealed that it correlated with the loss of a specific neuroinhibitory factor, rather than the presence of a neurotrophic fac- tor. This factor was later isolated and identified as GIF, its name derived from its ability to significantly impair neuronal survival and neurite outgrowth of cul- tured neurons [2]. It was postulated that a decrease of GIF in AD may contribute to the aberrant neuronal sprouting characteristic of this disease. Since its discovery, there has been considerable sci- entific interest in understanding the expression profile of GIF, and how the biochemical properties of GIF confer neurotrophic functions for this protein. In this minireview we will briefly discuss these studies and describe how GIF may influence neural recovery fol- lowing brain injury or neurodegenerative disease. Synthesis and secretion of GIF in the brain Cellular and temporal localization of GIF synthesis Whilst the MT1 and MT2 isoforms are ubiquitously synthesized throughout most tissues in mammals, GIF is predominantly found within the mammalian central nervous system (CNS) [3]. The less-studied MT4 iso- form has a restricted synthesis profile, being found almost exclusively in stratified squamous epithelia [4]. The cell-specific distribution of GIF protein and GIF mRNA has been widely studied, with conflicting results obtained. GIF has been reported at both transcript and protein levels in astrocytes only [1,5], in neurons only [6–8], or in both neurons and astrocytes [9–11]. Despite these conflicting results from a number of studies, the current general consensus is that the GIF protein is primarily synthesized in astrocytes, where it is found predominantly in the soma and fine processes of these cells. Astrocytic synthesis of GIF is mainly found in the cortex, brainstem and spinal cord [6]. Additionally however, there are also consistent reports of neuronal synthesis of GIF, albeit at seem- ingly much lower levels than within astrocytes. Neuro- nal synthesis of GIF is highly localized to specific subsets of cortical and hippocampal neurons, and is found within the axons and dendrites. Neuronal pro- duction of GIF is particularly associated with granule cells of the dentate gyrus in the hippocampus, in those neurons that store and release zinc at synapses [7]. While there is substantial evidence for expression of GIF mRNA in neurons from in situ hybridization studies, there is a discrepancy between the co-localiza- tion of GIF mRNA and protein, as very few studies are able to demonstrate neuronal localization of GIF at the protein level through immunohistochemistry or similar techniques. Such confirmation at the protein level has been hindered by the availability of appropri- ate GIF antibodies, and further studies are needed to resolve whether neurons synthesize basal levels of GIF protein. Neurodegenerative conditions under which GIF levels are altered The basal level of production of GIF in the CNS is considered to be quite low, particularly in comparison with the MT1 and MT2 isoforms that are more highly expressed by astrocytes in the brain. However, the levels of GIF are altered dramatically in the neurode- generative or traumatically injured brain. The best- characterized example of this is for AD. Indeed, many studies have analysed the amount of GIF present in AD brain extract compared with non-demented aged controls using both mRNA and protein assays. How- ever, these studies have yielded variable results, with some identifying up-regulation and others down-regu- lation of GIF levels in the AD brain compared with appropriate age-matched controls [2,12–16]. For instance, immunoreactivity was shown to be reduced in the AD cerebral cortex, specifically in the upper lay- ers of the gray matter, and this correlated with a sig- nificantly decreased number of GIF-positive astrocytes [2]. Conversely, other studies have reported elevated Function of GIF in injured and degenerative brain C. Howells et al. 2932 FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS GIF protein levels in AD patients when compared with age-matched controls [14]. While it is not clear why GIF levels vary so widely in these studies, it is thought that these results may indicate population- based variations in GIF expression levels. Hence, the expression levels of GIF are significantly reduced in Japanese AD patients [2,12], but do not appear to be reduced in AD patients of North American descent [15]. By contrast, the synthesis of GIF seems to be down- regulated in most other neurodegenerative diseases, including multiple-system atrophy, Parkinson’s disease, progressive supranuclear palsy and amyotrophic lateral sclerosis, and around senile plaques in Down syn- drome [17]. Interestingly, the level of GIF appears to correlate with neuronal loss, as GIF immunoreactivity disappears in areas with vast neuronal loss, but remains in less affected areas. Given its potent neurite growth-inhibitory proper- ties, it was predicted that the GIF levels might corre- late with the failure of the injured brain to regenerate. Indeed, a number of studies have confirmed that levels of GIF protein are up-regulated in reactive astrocytes surrounding cerebral infarcts, stab wounds or excito- toxic brain injuries. For instance, GIF mRNA was substantially up-regulated in reactive astrocytes sur- rounding degenerated neurons following ventricular injection of kainic acid [18]. Also, GIF was elevated in reactive astrocytes surrounding a stab wound to the brain at 3–4 days post-injury and remained elevated for almost a month [19,20]. The increase in GIF expression in response to these different types of brain injury was often observed in glial cells accumulating at the degenerating area, where the glial scar was begin- ning to form. Intriguingly, exogenously applied GIF has been shown to induce astrocyte proliferation and migration in vitro [14]. It is possible, then, that the up- regulation and secretion of GIF by astrocytes in the immediate vicinity of a lesion could contribute to the accumulation of reactive astrocytes at the injury site. Interestingly, one study has demonstrated that in the absence of GIF [Gif gene knockout (KO) mice] there were elevated levels of regeneration-associated mole- cules, such as growth-associated protein 43, following cortical cryolesion [21]. Hence, evidence gathered to date regarding GIF synthesis in response to traumatic brain injury indicates that GIF may be involved in the neuroinhibitory processes that are associated with glial scar formation. It is important to note that the synthesis of MT1 and MT2 in the injured or diseased brain is quite different from the synthesis of GIF. While GIF synthesis is gen- erally considered to be reduced in neurodegenerative diseases such as AD, amyotrophic lateral sclerosis and Down syndrome, MT1 and MT2 levels are consider- ably elevated in all of these conditions [22]. In the trau- matically injured brain, however, the synthesis of MT1 and MT2, as well as the synthesis of GIF, are up-regu- lated by reactive astrocytes in the vicinity of the lesion [23]. This suggests that these proteins may have different physiological roles in the stressed brain. Secretion of GIF The ability of GIF to inhibit neuronal survival and outgrowth occurs when the protein is applied exoge- nously to neurons. However, this has raised questions over the physiological relevance of this biological func- tion of GIF, because all MT isoforms have been con- sidered as solely intracellular proteins since their discovery more than 50 years ago. They lack any secre- tion signal sequences or other such extracellular traf- ficking signals, and their synthesis has generally been observed within the cytoplasm or nucleus of cells. However, in 2002 it was reported that GIF is secreted by cultured astrocytes [24]. The amount of GIF secreted by the cultured astrocytes was approximately 174 ngÆmg )1 of protein, measured using ELISA [24]. This study also determined that the amount of extra- cellular GIF was around 30% higher than the levels of intracellular GIF in these astrocyte cultures. Further- more, the absence of cell death suggested that GIF is actively secreted by cells, although the precise mecha- nism by which GIF is secreted remains unknown. Intriguingly, secretion of the MT1 and MT2 isoforms by cultured astrocytes has also recently been reported. The secretion of MT1 and MT2 by astrocytes appears to be regulated because the basal levels of protein secretion were low and could be stimulated through cytokine-activation of cultured astrocytes [25]. Whether GIF is secreted by a similar mechanism is currently not known. Understanding the specific situations which stimulate GIF secretion by astrocytes will prob- ably reveal important insights into the functional roles of this protein in the brain, and in particular its ability to inhibit neurite outgrowth (as described above). The functional role of GIF synthesis and secretion in the brain Taken together, the regulation of GIF synthesis by reactive astrocytes, and its subsequent secretion under certain conditions, could be intimately involved in regulating how the brain responds to and recovers from conditions such as physical or chemical trauma. Based upon the literature referred to above in this C. Howells et al. Function of GIF in injured and degenerative brain FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS 2933 minireview, we propose a possible model for how GIF might be involved in the cellular response to brain injury (Fig. 1). As neurons degenerate, the surrounding astrocytes respond by proliferating and assume a reac- tive phenotype. GIF synthesized by reactive astrocytes may be secreted by these cells to act upon neurons to initially decrease neurite outgrowth in response to the insult. As the condition progresses, perturbation to the interaction between neurons and glial cells may reduce GIF synthesis. Therefore, control over the release of neurotrophic factors, including GIF, by the reactive astrocytes would be compromised. For instance, in the later stages of neurodegenerative diseases the neuronal damage may interfere with the neuroglial interactions, lowering GIF production and secretion in reactive astrocytes. The reduction in GIF would lower the defences against free-radical-mediated attack and pro- tection from neuronal damage. In addition, the reduc- tion in GIF may also allow regenerative sprouting to occur. Physiological properties of GIF GIF has several key properties, based upon its unusual biochemical structure, which may influence its function in response to normal or stress-induced conditions. The relationship between protein structure and func- tion is the subject of detailed discussion in two other minireviews in this series [26,27]. In this minireview we will briefly describe the role of GIF in (a) regulation of metal ion homeostasis, (b) free radical scavenging and (c) neurite growth inhibition. Metal-binding properties of GIF and role in synaptic activity MTs are generally considered to have an important role in maintaining the homeostasis of key metal ions within the body. Like other MT isoforms, GIF binds both monovalent and divalent metal ions with high affinity. They have the ability to inhibit heavy metal toxicity [i.e. Cd(II), Hg(II)] and regulate the transport and storage of essential heavy metals [Cu(I) and Zn(II)]. However, GIF does not seem to be essential for metal-handling within the body, because studies have reported that GIF-deficient mice were not more prone to Zn or Cd toxicity compared with control ani- mals [26]. However, as GIF has been localized both intracellularly and extracellularly, it may have an important role in metal-related extracellular neuro- chemistry. It is important to note that the GIF is able to bind Cu(I) and Zn(II) concurrently. For example, GIF isolated from the human brain has been found to contain both Zn(II) and Cu(I), in a Cu 4 Zn 3 -GIF struc- ture [2]. The ability of GIF to bind redox-active metal ions, such as Cu(I), may suggest a crucial mechanism of how the protein is able to reduce oxidative stress. The metal-binding properties of GIF are discussed in greater detail in the two other minireviews of this series [26,27]. A clear indication of the physiological functions of GIF and its metal-binding properties has been gained from studies carried out under stress-induced condi- tions. For example, GIF KO mice are highly suscepti- ble to kainic acid-induced seizures. This was localized Neuron GIF GIF Low GIF Reactive astrocyte Astrocyte ROS GIF GIF ROS Axon injury ABC Fig. 1. Diagrammatic model describing the possible physiological roles of GIF at differ- ent stages following a traumatic brain injury. (A) Under normal conditions there is a low level of GIF synthesis within astrocytes and neurons. (B) Following brain injury, astro- cytes assume the reactive phenotype and increase their synthesis of GIF. Reactive astrocytes secrete GIF, which then acts to scavenge harmful ROS and blocks axon regeneration during the initial responses to the injury. (C) At later stages, interference in neuroglial interactions may decrease GIF production and secretion by surrounding astrocytes. The decreased levels of extra- cellular GIF would allow ROS-mediated attack on astrocytes and neurons, and may also promote excessive neurite sprouting. Function of GIF in injured and degenerative brain C. Howells et al. 2934 FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS to seizure-induced injury to CA3 hippocampal neu- rons, resulting in the GIF KO mice experiencing more convulsions and greater mortality than their wild-type littermates [28]. GIF-overexpressing mice experience much less kainic acid-induced brain damage compared with controls [26], implying that GIF may play an important protective role in response to kainic acid- induced seizures. One explanation of how GIF can protect against epileptic seizures is through its regulation of Zn(II) lev- els. Synaptically released zinc is thought to play a key role in neuronal signalling, and in response to kainic acid insult, neurons release Zn(II), as well as gluta- mate, from the synaptic cleft. Interestingly, neurons with a high GIF mRNA content are those known to store zinc in their axon terminals [7]. In addition, the synthesis of GIF within cultured cells led to a signifi- cant increase in intracellular Zn(II) stores within those cells [7]. GIF, through its zinc-binding properties, may act to recover synaptically released Zn(II) and enable its recycling into synaptic vesicles. Hence, the absence of GIF would lead to an accumulation of extrasynap- tic zinc, which would cause inappropriate synaptic firing and subsequent seizures. Interestingly, GIF may also have a role in regulating synaptic levels of zinc, as the GIF-deficient mice had a reduced content of Zn(II) within a number of brain regions [28]. ROS scavenging ability of GIF The coordination of redox-active metal ions to GIF may indirectly prevent ROS generation through metal chelation. Conversely, all MT isoforms have the ability to directly scavenge harmful ROS within the CNS and other tissues. ROS are highly reactive chemical com- pounds that are constantly generated by metabolic processes in vivo and cause serious damage to DNA, protein and membranes containing polyunsaturated fatty acids. ROS production is a normal by-product of metabolic activity, and under normal conditions, the ROS are effectively quenched before being liberated to cause damage. Regulation of ROS occurs through sev- eral ROS scavengers, or antioxidants. Antioxidants can be both enzymatic and non-enzymatic, and func- tion to protect cells against oxidative damage. Specific antioxidants include superoxide dismutase for superox- ide, catalase for hydrogen peroxide, and glutathione peroxidase for hydrogen peroxide and lipid peroxide. In addition, there are many other non-specific antioxi- dants, such as glutathione. Another efficient general free-radical scavenger is MT. MT is a strong nucleo- phil, because of its high cysteine content, enabling it to efficiently bind reactive ROS [29]. MT can function as a potent scavenger of hydrogen peroxide, hydroxyl, nitric oxide (NO) and superoxide radicals. Studies have shown that extracellular and intracellular GIF can protect cells from oxidative stress. There have been a number of studies investi- gating the specific free-radical scavenging ability of GIF. One such study reported that GIF was able to directly scavenge hydroxyl radicals generated in a Fenton-type reaction or by photolysis of hydrogen peroxide. In the same study, GIF was unable to scav- enge superoxide (generated in the hypoxanthine oxi- dase reaction) or NO (generated from NOC-7) [24]. The neuroprotection provided by extracellular GIF against free-radical-mediated attack was subsequently explored in vitro. To induce a condition indicative of oxidative stress, neurons were grown in a hyperoxic environment. Hyperoxia stimulates neuronal cells to differentiate or undergo cell death. Exogenous GIF prevented the induction of neuronal differentiation, quantified by the level of neurite outgrowth in young cortical neuronal cultures. The protein also prevented neuronal cell death in older cultures [24]. GIF not only protected neurons from oxidative stress, but was also shown to directly quench ROS within the cul- tured neurons. Using an indicator for intracellular ROS, GIF was shown to reduce ROS production in neurons. Intracellular GIF has been shown to protect against free-radical-mediated attack. The knocking down of endogenous GIF by antisense oligodeoxynucleotides in cultured cortical neurons was used to examine the neu- roprotection provided by intracellular GIF against oxi- dative stress. The reduction in intracellular GIF increased the rate of cortical neuronal death in a hyperoxic environment [24]. In a similar study, it was reported that fibroblasts expressing GIF were more resistant to cellular cytotoxicity induced by hydrogen peroxide [30]. Therefore, both intracellular and extra- cellular GIF demonstrates a strong ROS-scavenging property that is likely to protect neurons against oxi- dative damage in stress-induced conditions. Neurite growth-inhibitory property of GIF As previously discussed, GIF displays both neurotoxic and neuroinhibitory actions. The neuronal growth- inhibitory properties of GIF may have an important influence on the neural recovery from brain injury or neurodegenerative diseases. The presence of GIF was neurotoxic to cultured rat cortical neurons, inhibited neurite formation in developing neurons and delayed neurite elongation [2,24,31]. Importantly, GIF inhibited regenerative sprouting following axonal C. Howells et al. Function of GIF in injured and degenerative brain FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS 2935 transection of mature neurons [31]. However, in the absence of brain extract (either AD or from the nor- mal brain) GIF promotes neuron survival of cultured cortical neurons [31]. The neuroinhibitory action of GIF is very specific to this MT isoform and can be attributed to the small differences in the protein sequence of this isoform compared with all other mammalian MTs. The human GIF amino acid sequence is 70% similar to human MT2, retaining all the 20 conserved cysteine residues [2]. The only structural differences between GIF and MT1 and MT2 include a Cys-Pro-Cys-Pro(6–9) motif and Thr5 in the b-domain of GIF and a different amino acid structure in the a-domain [32]. Structural and cell biology studies have revealed that the Cys-Pro-Cys-Pro(6–9) motif seems to be critical for the biological activity of GIF. Mutations in this motif, specifically changing the two Pro residues to Ala and Ser (found in human MT2) abolished the neuroinhibi- tory activity of GIF [33]. Evidence from studies using the inactive mutant of Zn 7 GIF also liberated similar results, showing that despite the contrasting biological activities of GIF compared with MT1 and MT2, the metal-binding affinities remain comparable. However, the precise spatial structure and the mechanism behind the unique biological activity of GIF remain to be elucidated. Subsequent studies have investigated whether GIF acts in a neuroinhibitory manner when administered directly into the brain following traumatic brain injury. In one such study, the injection of GIF into the site of a stab wound promoted tissue repair, and the area of the stab wound treated with GIF was significantly smaller than those of control rats [34]. Interestingly, GIF showed dose-dependent activity, with a high dose being detrimental to tissue repair [34]. In addition, motoneurons transfected with GIF prevented loss of injured facial motoneurons [35]. It remains to be eluci- dated why GIF has neuroprotective functions when administered to the injured brain, versus its neuro- inhibitory actions upon cultured neurons. Current thoughts on the role of GIF in AD Since its discovery in 1991 as a factor that might be deficient in the AD brain, a number of studies have investigated the role of GIF in the pathogenesis of AD. While this has focussed primarily on the neuronal inhibitory properties of GIF, several recent studies have provided new insight into other mechanisms through which GIF might influence the disease process in AD. Role of the neurite growth-inhibitory properties of GIF in AD There have been extensive studies examining the role of GIF in AD, linked to its initial discovery as a factor deficient in the AD brain. There remains no clear con- sensus on the role of GIF in the pathogenesis of AD, and therefore we will briefly review some of the current thoughts on the role of GIF in AD. There are numer- ous pathological hallmarks in AD that are commonly accompanied by neuronal alterations. These physical alterations include aberrant neurite sprouting and sig- nificant neuronal loss. One hypothesis for why there is pronounced neural dysfunction and death is the presence of increased neu- rotrophic activity in the AD brain. It was on this assumption that GIF was first discovered as a neuro- nal growth-inhibitory factor, and a lack of GIF might contribute to the generation of neurofibrillary changes within the AD brain, including inappropriate neurite sprouting. Abnormal neurite sprouting might then lead to neuronal exhaustion and eventually cell death. In vitro studies have clearly demonstrated the ability of GIF to block neurite outgrowth, supporting the initial proposal of Uchida et al. [2] that a lack of GIF might be involved in AD pathogenesis. However, postmor- tem human studies have provided mixed results on the level of GIF present in the AD brain. The generation of GIF KO or GIF overexpressing mice with tau- based experimental mouse models of AD might pro- vide considerable insight into the potential role of GIF in neurofibrillary changes associated with AD. Potential role of metal-binding/exchange properties of GIF in AD One of the primary pathological hallmarks of AD is the formation of b-amyloid (Ab) plaques, composed primarily of Ab(1–40) and Ab(1–42) peptides, which associate to form abnormal extracellular deposits of fibrils and amorphous aggregates [36]. Ab is a metallo- protein that possesses high- and low-affinity Cu(I)- and Zn(II)-binding sites. Furthermore, metal ion homeostasis within the AD brain is dramatically unbalanced and is proposed to be involved in the pathology of Ab. For example, within the amyloid pla- ques the Cu(I) and Fe(III) ⁄ Zn(II) concentrations were  0.4 and  1mm respectively, compared with 70 and 340–350 lm, respectively, in healthy neocortical paren- chyma [37]. The close association between metal ions and Ab has prompted many groups to investigate numerous metal chelators to establish whether they have the potential to modify Ab pathogenesis in AD. Function of GIF in injured and degenerative brain C. Howells et al. 2936 FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS Intriguingly, GIF has strong Cu(I)- and Zn(II)-bind- ing efficiencies, suggesting that it may be able to mod- ify metal-induced Ab aggregation in AD. In this context, it has recently been reported that Zn 7 GIF was shown to remove Cu from aggregated Ab(1–40)-Cu(II) with the concomitant binding of Zn, leading to the for- mation of SDS-soluble monomeric zinc-bound Ab and soluble copper-bound GIF [38]. Therefore, the metal swap led to simultaneous modification of the final form of Ab(1–40) and suggests that it caused the de-aggregation of Ab. In a therapeutic context, this indicates that MT might potentially promote the clear- ance of Ab plaques. However, it is important to note that recent therapeutic approaches have been success- ful in clearing Ab plaques in clinical trials, but not for reducing neurodegeneration in the AD brain [39]. It is important to note that while Ab aggregation can be induced by both Cu(II) and Zn(II), only the Cu(II)- induced aggregation of Ab is toxic. The neurotoxicity of Cu(II)-induced Ab aggregation is related to the genera- tion of ROS through the redox cycling of Cu. In this regard, GIF has been demonstrated to not only prevent Ab aggregation, but also block the generation of ROS by Ab-Cu(II) [27,38]. Therefore, the ability of GIF to redox-silence metal ions and directly scavenge ROS (dis- cussed above) provide two distinct mechanisms through which GIF can act to protect against Ab pathogenesis and neurotoxicity in AD (Fig. 2). Conclusion The discovery of a brain-specific MT isoform, GIF, in 1991, sparked considerable interest in understanding the role of all MTs in the brain, and particularly within the injured or diseased brain. In the case of GIF, the protein has many neuroprotective properties that could provide vital protection during stress-induced conditions. Studies have already focused on the ability of GIF to protect against Ab pathology and neurotoxic- ity in AD, with promising results. By contrast, GIF also demonstrates a unique neuroinhibitory property, which may promote cellular survival and repair following injury, but could also be detrimental in neurodegenera- tive diseases. The studies to date have only just started to investigate and understand the physiological roles of GIF within the brain. Further studies are required to determine the function of GIF within the normal, injured and neurodegenerative brain, and to establish the therapeutic potential of the protein. Acknowledgements This work was supported by an Australian Research Council (ARC) Discovery Project Grant (DP0556630; RSC), and funding from the Jack & Ethel Goldin Foundation (Alzheimer’s Australia). RSC holds an ARC Research Fellowship. References 1 Uchida Y & Tomonaga M (1989) Neurotrophic action of Alzheimer’s disease brain extract is due to the loss of inhibitory factors for survival and neurite formation of cerebral cortical neurons. Brain Res 481, 190–193. 2 Uchida Y, Takio K, Titani K, Ihara Y & Tomonaga M (1991) The growth inhibitory factor that is deficient in the Alzheimers-disease brain is a 68-amino acid metallo- thionein-like protein. Neuron 7, 337–347. Cu-GIF + Reducing agent Reducing agent Zn-GIF + + Aβ-Zn i) Aβ β -Cu(II) A β -Cu(I) A β -Cu(II) A β -Cu(II)A β -Cu(I)A β -Cu(II) O 2 ROS O 2 ROS + ii ) Zn-GIF Cu-GIF ) AB Fig. 2. A diagrammatic model describing the possible protective properties of GIF against Ab pathogenesis and neurotoxicity in Alzheimer’s disease. (A) In the presence of a reducing agent, the copper coordinated to the Ab can undergo redox cycling to produce harmful ROS that damage the neurons. (B) MT is likely to protect against Ab-Cu(II) by a number of mechanisms: Zn 7 GIF is proposed to undergo a transmetalla- tion event with the Ab-Cu(II), which removes the redox-active Cu(II) from the Ab, coordinating it to MT as redox-stable Cu(I), while simulta- neously Ab coordinates redox-inert Zn. This event would prevent the generation of ROS. ZnGIF or CuGIF could also directly scavenge ROS. C. Howells et al. Function of GIF in injured and degenerative brain FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS 2937 3 Palmiter RD, Findley SD, Whitmore TE & Durnam DM (1992) MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci U S A 89, 6333–6337. 4 Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP & Palmiter RD (1994) Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33, 7250–7259. 5 Nakajima K & Suzuki K (1995) Immunochemical detec- tion of metallothionein in brain. Neurochem Int 27, 73–87. 6 Choudhuri S, Kramer KK, Berman NE, Dalton TP, Andrews GK & Klaassen CD (1995) Constitutive expression of metallothionein genes in mouse brain. Toxicol Appl Pharmacol 131, 144–154. 7 Masters BA, Quaife CJ, Erickson JC, Kelly EJ, Froelick GJ, Zambrowicz BP, Brinster RL & Palmiter RD (1994) Metallothionein-III is expressed in neurons that sequester zinc in synaptic vesicles. J Neurosci 14, 5844–5857. 8 Gong YH & Elliott JL (2000) Metallothionein expres- sion is altered in a transgenic murine model of familial amyotrophic lateral sclerosis. Exp Neurol 162, 27–36. 9 Yamada M, Hayashi S, Hozumi I, Inuzuka T, Tsuji S & Takahashi H (1996) Subcellular localization of growth inhibitory factor in rat brain: light and electron microscopic immunohistochemical studies. Brain Res 735, 257–264. 10 Yuguchi T, Kohmura E, Sakaki T, Nonaka M, Yamada K, Yamashita T, Kishiguchi T, Sakaguchi T & Hayakawa T (1997) Expression of growth inhibitory factor mRNA after focal ischemia in rat brain. J Cereb Blood Flow Metab 17, 745–752. 11 Zheng H, Berman NE & Klaassen CD (1995) Chemical modulation of metallothionein I and III mRNA in mouse brain. Neurochem Int 27, 43–58. 12 Tsuji S, Kobayashi H, Uchida Y, Ihara Y & Miyatake T (1992) Molecular cloning of human growth inhibitory factor cDNA and its down-regulation in Alzheimer’s disease. EMBO J 11, 4843–4850. 13 Yu WH, Lukiw WJ, Bergeron C, Niznik HB & Fraser PE (2001) Metallothionein III is reduced in Alzheimer’s disease. Brain Res 894, 37–45. 14 Carrasco J, Giralt M, Molinero A, Penkowa M, Moos T & Hidalgo J (1999) Metallothionein (MT)-III: generation of polyclonal antibodies, comparison with MT-I+II in the freeze lesioned rat brain and in a bioassay with astrocytes, and analysis of Alzheimer’s disease brains. J Neurotrauma 16, 1115–1129. 15 Erickson JC, Sewell AK, Jensen LT, Winge DR & Palmiter RD (1994) Enhanced neurotrophic activity in Alzheimers-disease cortex is not associated with down-regulation of metallothionein-III (GIF). Brain Res 649, 297–304. 16 Amoureux MC, Van Gool D, Herrero MT, Dom R, Colpaert FC & Pauwels PJ (1997) Regulation of metallothionein-III (GIF) mRNA in the brain of patients with Alzheimer disease is not impaired. Mol Chem Neuropathol 32, 101–121. 17 Sogawa CA, Asanuma M, Sogawa N, Miyazaki I, Nakanishi T, Furuta H & Ogawa N (2001) Localiza- tion, regulation, and function of metallothionein-III ⁄ growth inhibitory factor in the brain. Acta Med Okayama 55, 1–9. 18 Kim D, Kim EH, Kim C, Sun W, Kim HJ, Uhm CS, Park SH & Kim H (2003) Differential regulation of metallothionein-I, II, and III mRNA expression in the rat brain following kainic acid treatment. Neuroreport 14, 679–682. 19 Hozumi I, Inuzuka T, Hiraiwa M, Uchida Y, Anezaki T, Ishiguro H, Kobayashi H, Uda Y, Miyatake T & Tsuji S (1995) Changes of growth inhibitory factor after stab wounds in rat brain. Brain Res 688, 143–148. 20 Hozumi I, Inuzuka T, Ishiguro H, Hiraiwa M, Uchida Y & Tsuji S (1996) Immunoreactivity of growth inhibi- tory factor in normal rat brain and after stab wounds– an immunocytochemical study using confocal laser scan microscope. Brain Res 741, 197–204. 21 Carrasco J, Penkowa M, Giralt M, Camats J, Molinero A, Campbell IL, Palmiter RD & Hidalgo J (2003) Role of metallothionein-III following central nervous system damage. Neurobiol Dis 13, 22–36. 22 Hidalgo J, Aschner M, Zatta P & Vasa ´ k M (2001) Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull 55, 133–145. 23 Chung RS, Adlard PA, Dittmann J, Vickers JC, Chuah MI & West AK (2004) Neuron-glia communication: metallothionein expression is specifically up-regulated by astrocytes in response to neuronal injury. J Neuro- chem 88, 454–461. 24 Uchida Y, Gomi F, Masumizu T & Miura Y (2002) Growth inhibitory factor prevents neurite extension and the death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging. J Biol Chem 277, 32353–32359. 25 Chung RS, Penkowa M, Dittmann J, King CE, Bartlett C, Asmussen JW, Hidalgo J, Carrasco J, Leung YKJ, Walker AK et al. (2008) Redefining the role of metallo- thionein within the injured brain – extracellular metallo- thioneins play an important role in the astrocyte-neuron response to injury. J Biol Chem 283, 15349–15358. 26 Faller P (2010) Neuronal growth inhibitory factor (metallothionein-3): reactivity and structure of metal- thiolate clusters. FEBS J 277, 2921–2930. 27 Ding ZC, Ni FY & Huang ZX (2010) Neuronal growth inhibitory factor (metallothionein-3): structure-function relationships. FEBS J 277, 2912–2920. 28 Erickson JC, Hollopeter G, Thomas SA, Froelick GJ & Palmiter RD (1997) Disruption of the metallothionein- Function of GIF in injured and degenerative brain C. Howells et al. 2938 FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS III gene in mice: analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J Neurosci 17, 1271–1281. 29 Meloni G, Faller P & Vasak M (2007) Redox silencing of copper in metal-linked neurodegenerative disorders reaction of Zn(7)metallothionein-3 with Cu 2 + ions. J Biol Chem 282, 16068–16078. 30 You HJ, Lee KJ & Jeong HG (2002) Overexpression of human metallothionein-III prevents hydrogen peroxide- induced oxidative stress in human fibroblasts. FEBS Lett 521, 175–179. 31 Chung RS, Vickers JC, Chuah MI, Eckhardt BL & West AK (2002) Metallothionein-III inhibits initial neurite formation in developing neurons as well as postinjury, regenerative neurite sprouting. Exp Neurol 178, 1–12. 32 Sewell AK, Jensen LT, Erickson JC, Palmiter RD & Winge DR (1995) Bioactivity of metallothionein-3 correlates with its novel beta-domain sequence rather than metal-binding properties. Biochemistry 34, 4740–4747. 33 Hasler DW, Jensen LT, Zerbe O, Winge DR & Vasak M (2000) Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein. Biochemistry 39, 14567–14575. 34 Hozumi I, Uchida Y, Watabe K, Sakamoto T & Inuzuka T (2006) Growth inhibitory factor (GIF) can protect from brain damage due to stab wounds in rat brain. Neurosci Lett 395, 220–223. 35 Sakamoto T, Kawazoe Y, Uchida Y, Hozumi I, Inuzuka T & Watabe K (2003) Growth inhibitory factor prevents degeneration of injured adult rat motoneurons. Neuroreport 14, 2147–2151. 36 Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430, 631–639. 37 Lovell MA, Robertson JD, Teesdale WJ, Campbell JL & Markesbery WR (1998) Copper, iron and zinc in Alz- heimer’s disease senile plaques. J Neurol Sci 158, 47–52. 38 Meloni G, Sonois V, Delaine T, Guilloreau L, Gillet A, Teissie J, Faller P & Vasak M (2008) Metal swap between Zn-7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. Nat Chem Biol 4, 366–372. 39 Holmes C, Boche D, Wilkinson D, Yadegarfur G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW et al. (2008) Long-term effects of Ab 42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo controlled phase I trial. Lancet 372, 216–223. C. Howells et al. Function of GIF in injured and degenerative brain FEBS Journal 277 (2010) 2931–2939 ª 2010 The Authors Journal compilation ª 2010 FEBS 2939 . MINIREVIEW Neuronal growth-inhibitory factor (metallothionein-3): evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative. interest in understanding the role of all MTs in the brain, and particularly within the injured or diseased brain. In the case of GIF, the protein has many